8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Shannon Powlowski
6.5
- - Regulatory Submission
- - 8 weeks May - July 2024
- - Pharmaceutical Company
Reviewed:
Regulatory submission was incomplete, required additional work.
The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.
Jonathon Deckow
9.3
- - Market Access Strategy
- - 6 weeks January - February 2024
- - Pharmaceutical Company
Reviewed:
Strategic market access analysis, insightful recommendations.
The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.
Carolyn Rath
9
- - Process Development
- - 12 weeks March - May 2024
- - Biotech Company
Reviewed:
Expert process development, enhanced efficiency.
The process development services enhanced our manufacturing efficiency significantly. The team's expertise in process optimization was evident, and they provided valuable insights that improved our production workflow.
Cecilia Stanton
8.9
- - Medical Writing
- - 5 weeks October - November 2023
- - Biotech Company
Reviewed:
Top-quality medical writing, clear and precise documents.
The medical writing services provided were of top quality. The documents were clear, precise, and tailored to meet the specific requirements of our regulatory submissions. The team's expertise was evident throughout the process.
Bennie Herzog
6
- - Health Technology Assessment
- - 8 weeks July - September 2024
- - Pharmaceutical Company
Reviewed:
Health technology assessment was superficial, lacked thorough analysis.
The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.
Lauren Hettinger
6.2
- - Clinical Protocol Design
- - 10 weeks January - March 2024
- - Pharmaceutical Company
Reviewed:
Inconsistent quality of deliverables, frequent revisions needed.
The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.
Kim Yundt
9.2
- - Data Visualization
- - 3 weeks December 2023
- - Pharmaceutical Company
Reviewed:
Highly effective data visualization, easy to interpret and impactful.
The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.
